Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?

Status Completed

Clinical Trial Summary

This study evaluates whether patients with Clostridium difficile infection (CDI) who are treated with fidaxomicin have less contamination of their skin and surrounding environment with spores of C. difficile than patients treated with other drugs (metronidazole or vancomycin)

Clinical Trial Description

Fidaxomicin is a newly licensed drug for the treatment of CDI. Patients treated with fidaxomicin have a significantly lower C. difficile spore count in their faeces than patients who receive alternative drugs (metronidazole or vancomycin). In vitro evidence has shown that the drug persists in the gut for several weeks after treatment has finished and also prevents the outgrowth of spores. These findings suggest that fidaxomicin therapy could be associated with less contamination of CDI patient's skin and their surrounding environment than metronidazole or vancomycin therapy. This prospective, case control study aims to investigate this hypothesis by measuring C. difficile spore counts in patient's stool samples, on their skin and in the surrounding environment. Results for patients receiving fidaxomicin will be compared with those on either metronidazole or vancomycin. If fidaxomicin therapy does reduce contamination levels, it might be a useful adjunct to existing measures used to control CDI in healthcare settings, particularly in outbreak situations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02461901
Study type	Observational
Source	University of Leeds
Contact
Status	Completed
Phase
Start date	January 2015
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02214771` - Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients	N/A
Withdrawn	`NCT01552668` - Fidaxomicin to Prevent Clostridium Difficile Colonization	Phase 4
Recruiting	`NCT03325855` - Fecal Microbiota Transplant National Registry
Not yet recruiting	`NCT03586206` - Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
Suspended	`NCT03350711` - A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
Withdrawn	`NCT03643887` - Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients	Phase 2
Terminated	`NCT04000555` - Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)	Phase 4
Terminated	`NCT03065374` - Treatment for Clostridium-difficile Infection With IMM529	Phase 1/Phase 2
Completed	`NCT03710694` - Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)	N/A
Completed	`NCT02865616` - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)	Phase 1
Recruiting	`NCT04940468` - High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology	N/A
Completed	`NCT02589847` - Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	Phase 2
Not yet recruiting	`NCT01942447` - Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis	N/A
Active, not recruiting	`NCT02086916` - Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection	N/A
Completed	`NCT01230957` - Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults	Phase 2
Completed	`NCT01241552` - A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	Phase 3
Not yet recruiting	`NCT04567134` - Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
Completed	`NCT04075422` - Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Recruiting	`NCT03712722` - Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
Recruiting	`NCT05192148` - Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile	N/A